We report significant activity this quarter, setting the pace for a strong start to 2019. Clinical planning has commenced for our CUREfilm Blue™ (Sildenafil 50mg) product on the heels of a pre-IND meeting with the FDA in March. We recently announced our planned acquisition of Chemistry Holdings which will bring novel and complementary formulation technology to our CUREfilm™ platform as well as add unique oral dosage forms, extending the breadth of CURE’s oral delivery platform. The combined operating capital and technology associated with this transaction open the door to new product opportunities and potential improvements to our product pipeline. New product opportunities are further made possible with our expanded DEA registration for the manufacture of whole-plant derived cannabis products and synthetic CBD. Read further for more on these and other updates this quarter.
~ Jessica Rousset, COO, CURE Pharmaceutical
CURE to acquire Chemistry Holdings Inc.
On April 1, we announced our plans to acquire Chemistry Holdings Inc. (“Chemistry Holdings”, “CH”), a formulation technology company that is developing innovative delivery systems for a variety of industries, in an all-stock transaction.
The acquired technology includes a novel chewable delivery system, nanoemulsions, microemulsions, microcapsules and taste masking solutions. These technologies complement and expand the CUREfilm™ platform to enable delivery of a wider range of active ingredients at higher doses. The combined technologies create a highly versatile platform for both immediate and controlled-release drug delivery.
For more details on the deal, check out our website at the link below.
READ THE FAQ’S
Planning begins for clinical trials for CUREfilm Blue™
We’ve successfully completed a pre-IND (Investigational New Drug) review with the U.S. Food and Drug Administration (FDA). The FDA provided feedback supportive of our clinical development plans for CUREfilm Blue™, a soluble thin film for oral administration of sildenafil citrate (Viagra™) to treat erectile dysfunction (ED).
With this feedback, we anticipate submitting the IND application in preparation for multiple clinical trials starting in Q3 of 2019.
A major milestone with a Schedule 1 U.S. DEA license
In November 2018, CURE became the first and only oral thin film company with U.S. Drug Enforcement Administration (DEA) approval to manufacture cannabinoid-based pharmaceuticals. We secured a new registration with the DEA as a manufacturer authorized to handle Schedule 1 controlled substances.
In February 2019, this license was expanded to include both cannabis plant extracts and synthetic cannabidiol (CBD), allowing us to develop and manufacture cannabis-derived and synthetic cannabidiol-based pharmaceutical products.
The Schedule 1 approval positions us well to partner with companies in the pharmaceutical cannabinoid space looking for proprietary next-generation formulations.
A partnership for global healthcare awareness
We’re thrilled to announce a global healthcare awareness initiative with United Smart Cities for the purpose of educating, informing and providing the next generation healthcare solutions to the world’s 7.3 billion citizens.
In a joint effort to address escalating healthcare costs, CURE and United Smart Cities will seek to promote education and innovation in delivering cost-effective and sustainable treatments to the world’s population.
CUREfilm™ featured on television
Our cutting-edge CUREfilm™ technology was featured on television in American Health Journal’s “Innovations In Medicine: Medical Marijuana,” a show that went on to win a 2019 AVA Digital Award, Gold.
We’re seeking a Senior Analytical Chemist! To apply or for more information on this role, please see the job listing here.
This press release contains forward-looking statements that involve risks and uncertainties. There are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the ability to successfully market our products, the difficulty in predicting the timing or outcome of other product research and development efforts, potential product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect the Company’s judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. On February 28, 2017, and ending on August 28, 2020, Liviakis Financial Communications, Inc. (LFC) was retained by CURE Pharmaceutical Holding Corp. (CURR) in various consulting capacities including strategic management planning, investor relations and other business development responsibilities. LFC was compensated 1,000,000 restricted common stock under rule 144. Officers and employees of LFC will buy or sell shares in CURE Pharmaceutical Holding Corp. prior, during or after this release. LFC advises CURE Pharmaceutical Holding Corp. but does not provide investment advice. LFC is not a registered investment advisor or broker-dealer. All material provided regarding CURE Pharmaceuticals Holding Corp. including, but not limited to its history, corporate status, and other developments was prepared using information approved and signed off by CURE Pharmaceutical Holding Corp. management as approved for public dissemination. Although the information contained herein is believed to be reliable, LFC makes no warranties as to the accuracy of the description of any of the content herein and accepts no liability for how readers may choose to utilize it.